机构：[1]School of International Pharmaceutical Business, China Pharmaceutical University - Jiangning Campus, Nanjing, China[2]Department of Breast Surgery, Guangdong Traditional Chinese Medical Hospital, Guangzhou, China[3]Department of Breast Surgery, Beijing Hospital, Beijing, China[4]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China[5]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China[6]Department of Breast Surgery, Shandong Cancer Hospital, Jinan, China[7]Health Economic and Outcome Research Division, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China
第一作者机构：[1]School of International Pharmaceutical Business, China Pharmaceutical University - Jiangning Campus, Nanjing, China
推荐引用方式(GB/T 7714)：
X. Guan,H-C. Li,Q-J. Chen,et al.Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer[J].ANNALS OF ONCOLOGY.2021,32:S45-S45.doi:10.1016/j.annonc.2021.03.072.
APA：
X. Guan,H-C. Li,Q-J. Chen,B. Hua,J-J. Li...&A-X. Ma.(2021).Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer.ANNALS OF ONCOLOGY,32,
MLA：
X. Guan,et al."Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer".ANNALS OF ONCOLOGY 32.(2021):S45-S45
医学